FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4387485265> ?p ?o ?g. }

• W4387485265 abstract "Background The widespread use of the integrase strand transfer inhibitor (INSTI) dolutegravir in first-line and second-line antiretroviral therapy (ART) might facilitate emerging resistance. The DTG RESIST study combined data from HIV cohorts to examine patterns of drug resistance mutations (DRMs) and identify risk factors for dolutegravir resistance. Methods We included cohorts with INSTI resistance data from two collaborations (ART Cohort Collaboration, International epidemiology Databases to Evaluate AIDS in Southern Africa), and the UK Collaborative HIV Cohort. Eight cohorts from Canada, France, Germany, Italy, the Netherlands, Switzerland, South Africa, and the UK contributed data on individuals who were viraemic on dolutegravir-based ART and underwent genotypic resistance testing. Individuals with unknown dolutegravir initiation date were excluded. Resistance levels were categorised using the Stanford algorithm. We identified risk factors for resistance using mixed-effects ordinal logistic regression models. Findings We included 599 people with genotypic resistance testing on dolutegravir-based ART between May 22, 2013, and Dec 20, 2021. Most had HIV-1 subtype B (n=351, 59%), a third had been exposed to first-generation INSTIs (n=193, 32%), 70 (12%) were on dolutegravir dual therapy, and 18 (3%) were on dolutegravir monotherapy. INSTI DRMs were detected in 86 (14%) individuals; 20 (3%) had more than one mutation. Most (n=563, 94%) were susceptible to dolutegravir, seven (1%) had potential low, six (1%) low, 17 (3%) intermediate, and six (1%) high-level dolutegravir resistance. The risk of dolutegravir resistance was higher on dolutegravir monotherapy (adjusted odds ratio [aOR] 34·1, 95% CI 9·93–117) and dolutegravir plus lamivudine dual therapy (aOR 9·21, 2·20–38·6) compared with combination ART, and in the presence of potential low or low (aOR 5·23, 1·32–20·7) or intermediate or high-level (aOR 13·4, 4·55–39·7) nucleoside reverse transcriptase inhibitor (NRTI) resistance. Interpretation Among people with viraemia on dolutegravir-based ART, INSTI DRMs and dolutegravir resistance were rare. NRTI resistance substantially increased the risk of dolutegravir resistance, which is of concern, notably in resource-limited settings. Monitoring is important to prevent resistance at the individual and population level and ensure the long-term sustainability of ART. Funding US National Institutes of Health, Swiss National Science Foundation." @default.
• W4387485265 created "2023-10-11" @default.
• W4387485265 creator A5007109117 @default.
• W4387485265 creator A5012288385 @default.
• W4387485265 creator A5029832971 @default.
• W4387485265 creator A5034322602 @default.
• W4387485265 creator A5035631466 @default.
• W4387485265 creator A5049260734 @default.
• W4387485265 creator A5051367754 @default.
• W4387485265 creator A5051639117 @default.
• W4387485265 creator A5055994083 @default.
• W4387485265 creator A5060727664 @default.
• W4387485265 creator A5065094327 @default.
• W4387485265 creator A5069244385 @default.
• W4387485265 creator A5071500584 @default.
• W4387485265 creator A5076718956 @default.
• W4387485265 creator A5079562113 @default.
• W4387485265 creator A5081212694 @default.
• W4387485265 creator A5081694461 @default.
• W4387485265 creator A5089941167 @default.
• W4387485265 date "2023-10-01" @default.
• W4387485265 modified "2023-10-17" @default.
• W4387485265 title "HIV-1 drug resistance in people on dolutegravir-based antiretroviral therapy: a collaborative cohort analysis" @default.
• W4387485265 cites W1494300042 @default.
• W4387485265 cites W1967284000 @default.
• W4387485265 cites W1969028669 @default.
• W4387485265 cites W2085120686 @default.
• W4387485265 cites W2094811879 @default.
• W4387485265 cites W2116049022 @default.
• W4387485265 cites W2124248661 @default.
• W4387485265 cites W2133117185 @default.
• W4387485265 cites W2170578204 @default.
• W4387485265 cites W2286136427 @default.
• W4387485265 cites W2315476807 @default.
• W4387485265 cites W2345249642 @default.
• W4387485265 cites W2464927114 @default.
• W4387485265 cites W2588666346 @default.
• W4387485265 cites W2604690888 @default.
• W4387485265 cites W2925271821 @default.
• W4387485265 cites W2971871407 @default.
• W4387485265 cites W3025262438 @default.
• W4387485265 cites W3033313535 @default.
• W4387485265 cites W3159123512 @default.
• W4387485265 cites W3206822480 @default.
• W4387485265 cites W4220951996 @default.
• W4387485265 cites W4221062931 @default.
• W4387485265 cites W4224248546 @default.
• W4387485265 cites W4252454272 @default.
• W4387485265 cites W4297914773 @default.
• W4387485265 cites W4312194761 @default.
• W4387485265 doi "https://doi.org/10.1016/s2352-3018(23)00228-x" @default.
• W4387485265 hasPublicationYear "2023" @default.
• W4387485265 type Work @default.
• W4387485265 citedByCount "1" @default.
• W4387485265 crossrefType "journal-article" @default.
• W4387485265 hasAuthorship W4387485265A5007109117 @default.
• W4387485265 hasAuthorship W4387485265A5012288385 @default.
• W4387485265 hasAuthorship W4387485265A5029832971 @default.
• W4387485265 hasAuthorship W4387485265A5034322602 @default.
• W4387485265 hasAuthorship W4387485265A5035631466 @default.
• W4387485265 hasAuthorship W4387485265A5049260734 @default.
• W4387485265 hasAuthorship W4387485265A5051367754 @default.
• W4387485265 hasAuthorship W4387485265A5051639117 @default.
• W4387485265 hasAuthorship W4387485265A5055994083 @default.
• W4387485265 hasAuthorship W4387485265A5060727664 @default.
• W4387485265 hasAuthorship W4387485265A5065094327 @default.
• W4387485265 hasAuthorship W4387485265A5069244385 @default.
• W4387485265 hasAuthorship W4387485265A5071500584 @default.
• W4387485265 hasAuthorship W4387485265A5076718956 @default.
• W4387485265 hasAuthorship W4387485265A5079562113 @default.
• W4387485265 hasAuthorship W4387485265A5081212694 @default.
• W4387485265 hasAuthorship W4387485265A5081694461 @default.
• W4387485265 hasAuthorship W4387485265A5089941167 @default.
• W4387485265 hasConcept C114851261 @default.
• W4387485265 hasConcept C126322002 @default.
• W4387485265 hasConcept C142462285 @default.
• W4387485265 hasConcept C156957248 @default.
• W4387485265 hasConcept C159047783 @default.
• W4387485265 hasConcept C201903717 @default.
• W4387485265 hasConcept C2777302000 @default.
• W4387485265 hasConcept C2778451633 @default.
• W4387485265 hasConcept C2779502633 @default.
• W4387485265 hasConcept C2993143319 @default.
• W4387485265 hasConcept C3013748606 @default.
• W4387485265 hasConcept C54355233 @default.
• W4387485265 hasConcept C71924100 @default.
• W4387485265 hasConcept C72563966 @default.
• W4387485265 hasConcept C86803240 @default.
• W4387485265 hasConceptScore W4387485265C114851261 @default.
• W4387485265 hasConceptScore W4387485265C126322002 @default.
• W4387485265 hasConceptScore W4387485265C142462285 @default.
• W4387485265 hasConceptScore W4387485265C156957248 @default.
• W4387485265 hasConceptScore W4387485265C159047783 @default.
• W4387485265 hasConceptScore W4387485265C201903717 @default.
• W4387485265 hasConceptScore W4387485265C2777302000 @default.
• W4387485265 hasConceptScore W4387485265C2778451633 @default.
• W4387485265 hasConceptScore W4387485265C2779502633 @default.
• W4387485265 hasConceptScore W4387485265C2993143319 @default.
• W4387485265 hasConceptScore W4387485265C3013748606 @default.
• W4387485265 hasConceptScore W4387485265C54355233 @default.

• next